To explore the role of TNFR2 in tumor-enhancing inflammation and immune evasion, and to evaluate specific therapeutic strategies targeting the TNF-TNFR2 pathway, including monoclonal antibodies and bispecific antibodies.
Key Findings:
TNFR1 mediates cytotoxic signaling, while TNFR2 promotes tumor-enhancing inflammation and immunosuppression, highlighting the need for targeted therapies.
TNFR2 is predominantly expressed on regulatory T cells, myeloid-derived suppressor cells, and cancer-associated fibroblasts, contributing to immune evasion.
Targeting TNFR2 may help overcome resistance to immune checkpoint blockade therapies, potentially improving patient outcomes.
Interpretation:
The TNF-TNFR2 pathway plays a critical role in immune evasion within the tumor microenvironment, suggesting that selective targeting of TNFR2 could significantly enhance the efficacy of cancer immunotherapies.
Limitations:
Potential on-target toxicity associated with TNFR2 targeting could impact patient safety and treatment adherence.
Challenges in patient stratification for targeted therapies may limit the effectiveness of TNFR2-targeted approaches.
Context-dependent biology of TNFR2 complicates therapeutic approaches, necessitating careful consideration in treatment design.
Conclusion:
Targeting TNFR2 presents a promising strategy to address immune resistance in tumors and improve outcomes for patients undergoing immunotherapy.
Researchers from the Department of Urology at Fudan University Shanghai Cancer Center evaluated artificial intelligence (AI)–assisted communications in the preoperative setting to assess its impact on...
A new report released by the Union for International Cancer Control shows that people exposed over the long term to fine particulate matter (PM2.5) (such as vehicle exhaust, wildfires, wood burning) h...
